Analysts have raised their fair value estimate for MetLife from $91.86 to $93.00. This reflects slight adjustments to discount rates and growth assumptions.
What's in the News
- MetLife introduced a new Cancer Support benefit, expanding its Critical Illness Insurance to include personalized cancer care, access to top oncology specialists, and expert coordination through a partnership with Private Health Management (Key Developments).
- MetLife, Inc. will redeem all outstanding shares of its 3.850% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G. Redemption is scheduled for September 15, 2025. Regular dividends will be paid separately on that date to eligible shareholders (Key Developments).
- From April 1, 2025, to June 30, 2025, MetLife repurchased 6,546,520 shares, representing 0.97% of its shares for $510.08 million. This completes the buyback announced on May 1, 2024 (Key Developments).
- Between April 30, 2025, and July 31, 2025, MetLife completed the repurchase of 2,686,822 shares, representing 0.4% of its shares for $211.1 million under the buyback announced on April 30, 2025 (Key Developments).
Valuation Changes
- The Fair Value Estimate has risen slightly from $91.86 to $93.00.
- The Discount Rate has decreased marginally from 7.77% to 7.69%.
- Revenue Growth assumptions have edged up from 4.71% to 4.72%.
- The Net Profit Margin estimate has declined fractionally from 7.54% to 7.54%.
- The Future P/E Ratio has increased from 10.71x to 10.83x.
Have other thoughts on MetLife?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.